Year All2024202320222021202020192018201720152014 Apr 26, 2024 CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 Apr 24, 2024 CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 Mar 28, 2024 CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting Feb 27, 2024 CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer Jan 30, 2024 CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Jan 24, 2024 CG Oncology Announces Pricing of Upsized Initial Public Offering
Apr 24, 2024 CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
Feb 27, 2024 CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
Jan 30, 2024 CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares